Project Grant R21NS146759
- Federal Project Grant Award Summary Brigham and Women's Hospital Inc. received a $557,883 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded May 1, 2026, with a completion date of April 30, 2031. The award funds research investigating the pathogenic mechanisms of leucine-rich repeat kinase 2 (LRRK2) mutations, which are linked to familial...
- Federal Project Grant Award Summary Brigham & Women's Hospital Inc. received a $864,552 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective August 1, 2025, through July 31, 2027. The award funds research focused on the discovery and optimization of novel pharmaceutical compounds for treating essential tremor (ET), a chronic and progressive...
- Federal Grant Award Summary Brigham and Women's Hospital Inc. received a $479,687 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded March 6, 2026, with completion targeted for February 29, 2028. The award funds research to identify and restore mechanisms driving epilepsy associated with Dentatorubral-Pallidoluysian Atrophy (DRPLA), a rare...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $1.81 million Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded May 11, 2026, with a completion date of April 30, 2029. The grant supports research investigating LRRK2 (Leucine-Rich Repeat Kinase 2) signaling and its role in the progression of...
- Federal Project Grant Award Summary Brigham and Women's Hospital Inc. received a $549,256 Project Grant awarded on June 6, 2025, by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award supports a five-year research project with a completion date of May 31, 2030, investigating the regulation of astrocyte responses in central nervous system (CNS) inflammation, with...
- Federal Grant Award Summary Award Details: The National Institute of Neurological Disorders and Stroke (NINDS) awarded Emory University a $540,901 Project Grant (CFDA 93.853 – Extramural Research Programs in the Neurosciences and Neurological Disorders) on April 15, 2026, with a completion date of March 31, 2031. The research will be conducted at Emory's Atlanta, Georgia location. Research Scope: This research project investigates changes in molecular mechanisms of dopamine signaling in advanced...
- Federal Project Grant Award Summary The University of Alabama at Birmingham received a $2.72 million Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded June 1, 2025, with a completion date of May 31, 2027. This award funds investigator-initiated research examining the effects of 14-3-3 theta protein phosphorylation on vesicular transport and...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded The Johns Hopkins University a $155,000 project grant effective July 8, 2025 through June 30, 2027 under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853). The award supports the characterization of an aminoacyl-tRNA synthetase complex interacting multifunctional protein-2 (AIMP2) variant-linked mouse model of Parkinson's disease. The...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $460,625 to the University of Massachusetts Medical School on June 7, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. This exploratory research project, scheduled for completion by May 31, 2027, investigates the roles of the deubiquitylation pathway in TDP-43 (TAR DNA-binding protein 43) pathology relevant to...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $627,103 to the Research Foundation for Mental Hygiene, Inc. (operating through the New York State Psychiatric Institute) on June 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). This five-year Project Grant, with completion scheduled for May 31, 2031, supports fundamental neuroscience research investigating the role of...
Brigham and Women's Hospital Inc. received a $492,250 Project Grant award, effective August 1, 2026 through July 31, 2028, from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The research project, titled "Identification of the Palmitoyltransferase for Glucocerebrosidase Trafficking Receptor LIMP2 and Restoration of GBA1 Function in Parkinson Disease and Lewy Body Dementia," focuses on identifying and characterizing the palmitoyltransferase enzyme responsible for modifying the LIMP2 (Lysosome Membrane Protein 2) trafficking receptor. The work aims to elucidate how palmitoylation—the modification of proteins by the fatty acid palmitate—influences vesicle and protein trafficking pathways disrupted in synucleinopathies, a group of neurodegenerative disorders characterized by alpha-synuclein aggregation. The research deliverables include mechanistic studies on palmitoylation's role in glucocerebrosidase (GCase) trafficking through its LIMP2 receptor, with potential therapeutic applications for Parkinson Disease (PD), Parkinson Disease Dementia (PDD), and Dementia with Lewy Bodies (DLB). The investigation builds on preliminary findings demonstrating that inhibiting depalmitoylase APT1 (Acyl Protein Thioesterase-1) alleviates alpha-synuclein pathology and improves motor and cognitive phenotypes in PD/DLB model mice. The project will advance understanding of a novel therapeutic target space for disease modification in synucleinopathies and may inform future pharmacologic interventions targeting palmitoylation pathways.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $492.3k | 7/10/26 |